JP2016204396A5 - - Google Patents

Download PDF

Info

Publication number
JP2016204396A5
JP2016204396A5 JP2016179732A JP2016179732A JP2016204396A5 JP 2016204396 A5 JP2016204396 A5 JP 2016204396A5 JP 2016179732 A JP2016179732 A JP 2016179732A JP 2016179732 A JP2016179732 A JP 2016179732A JP 2016204396 A5 JP2016204396 A5 JP 2016204396A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
units
collagenase
src
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016179732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016204396A (ja
JP6498167B2 (ja
Filing date
Publication date
Priority claimed from US11/703,269 external-priority patent/US20070224184A1/en
Application filed filed Critical
Publication of JP2016204396A publication Critical patent/JP2016204396A/ja
Publication of JP2016204396A5 publication Critical patent/JP2016204396A5/ja
Application granted granted Critical
Publication of JP6498167B2 publication Critical patent/JP6498167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016179732A 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ Active JP6498167B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US60/775,690 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
US11/703,269 2007-02-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015095704A Division JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018182242A Division JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ

Publications (3)

Publication Number Publication Date
JP2016204396A JP2016204396A (ja) 2016-12-08
JP2016204396A5 true JP2016204396A5 (enExample) 2017-03-30
JP6498167B2 JP6498167B2 (ja) 2019-04-10

Family

ID=38325147

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2008556445A Active JP5775658B2 (ja) 2006-02-22 2007-02-22 セルライト処置用コラゲナーゼ
JP2015095704A Pending JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ
JP2016179732A Active JP6498167B2 (ja) 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ
JP2018182242A Active JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ
JP2019200656A Active JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2008556445A Active JP5775658B2 (ja) 2006-02-22 2007-02-22 セルライト処置用コラゲナーゼ
JP2015095704A Pending JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018182242A Active JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ
JP2019200656A Active JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ

Country Status (19)

Country Link
US (4) US20070224184A1 (enExample)
EP (1) EP1991258B1 (enExample)
JP (5) JP5775658B2 (enExample)
KR (2) KR20080108996A (enExample)
AU (1) AU2007221225B2 (enExample)
BR (1) BRPI0708186A2 (enExample)
CA (1) CA2643171C (enExample)
DK (1) DK1991258T3 (enExample)
ES (1) ES2553184T3 (enExample)
HR (1) HRP20151182T1 (enExample)
HU (1) HUE025918T2 (enExample)
IL (1) IL193639A (enExample)
MX (1) MX2008010767A (enExample)
NZ (1) NZ570642A (enExample)
PL (1) PL1991258T3 (enExample)
PT (1) PT1991258E (enExample)
RS (1) RS54372B1 (enExample)
SI (1) SI1991258T1 (enExample)
WO (1) WO2007100675A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
NZ556160A (en) * 2005-01-21 2009-11-27 Univ New York State Res Found Methods for treating adhesive capsulitis
US20090233885A1 (en) * 2006-07-14 2009-09-17 Duncan Diane I Compositions and Methods for Fat Reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
CA2852942C (en) * 2011-10-21 2023-01-10 Auxilium International Holdings, Inc. Method of treating or reducing efp
EP4015627B1 (en) 2012-01-12 2023-09-27 Endo Global Ventures Clostridium histolyticum enzyme
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
EP4591945A2 (en) 2017-03-01 2025-07-30 Endo Operations Limited Apparatus and method for assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
AU2019341663C1 (en) * 2018-09-18 2025-08-07 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
WO2020142701A1 (en) 2019-01-06 2020-07-09 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
US11872267B2 (en) 2019-10-15 2024-01-16 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
BR112022010042A2 (pt) * 2019-11-26 2022-08-16 Standard Of Care Corp Composições de hialuronidase e métodos de uso da mesma para tratar celulite
EP4522283A1 (en) * 2022-05-10 2025-03-19 Endo Global Aesthetics Limited Methods of reducing collagenase-mediated bruising in a subject having cellulite

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
EP0766733A4 (en) * 1994-06-24 1998-06-10 Boehringer Mannheim Corp GET A CLEAN MIX OF COLLAGENASE AND TWO OTHER PROTEASES FROM CLOSTRIDIUM HISTOLYTICUM
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
EP1024788A1 (en) * 1997-10-03 2000-08-09 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
DE60014931D1 (de) * 1999-08-20 2004-11-18 Howard Murad Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens
NZ556160A (en) * 2005-01-21 2009-11-27 Univ New York State Res Found Methods for treating adhesive capsulitis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US20210169844A1 (en) * 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions

Similar Documents

Publication Publication Date Title
JP2016204396A5 (enExample)
JP2018199733A5 (enExample)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2015187125A5 (enExample)
Marchetti et al. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5‐year study of 51 patients
JP2022088517A (ja) 前立腺癌を治療するための組成物
HRP20151182T1 (hr) Kolagenaza za tretiranje celulita
JP2020033360A5 (enExample)
EP2292235A3 (de) Methotrexat-Lösungen
JP2023120246A5 (enExample)
JP2018507243A5 (enExample)
JP2014530873A5 (enExample)
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
Guslandi et al. Rifaximin for active ulcerative colitis
Zhou et al. Clinical observation on the treatment of oral lichen planus with total glucosides of paeony capsule combined with corticosteroids
Cui et al. Effect of single intra-cutaneous injection for acute thoracic herpes zoster and incidence of postherpetic neuralgia
Li et al. Efficacy of bilateral catheter superficial parasternal intercostal plane blocks using programmed intermittent bolus for opioid-sparing postoperative analgesia in cardiac surgery with sternotomy: a randomized, double-blind, placebo-controlled trial
Librodo et al. Chronotherapeutic drug delivery
JP2016505050A5 (enExample)
JP2009539916A5 (enExample)
Aggarwal et al. Comparative analysis of pain during anesthesia and no-scalpel vasectomy procedure among three different local anesthetic techniques
JP2019535830A5 (enExample)
JP2005529152A5 (enExample)
AU2019385373A1 (en) Application of chidamide in combination with R-CHOP, and drug combination
de Kam PhD et al. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation